Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, learn how Moderna is expanding its manufacturing footprint in Massachusetts, GSK is advancing new research collaborations under the LTZ Fleming Initiative, and the FDA commissioner highlights how early and late movers can benefit from the National Priority Voucher program.
Moderna has announced a $140 million investment to enhance its Massachusetts manufacturing capacity, a move that supports long-term scale-up for its mRNA vaccine and therapeutic pipeline. The expansion is part of the company’s broader strategy to strengthen U.S.-based production as demand for mRNA platforms continues to rise.
GSK is launching new research collaborations through the LTZ Fleming Initiative, aimed at accelerating scientific…
